8-KRegulation FDExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Regulation FD Disclosure (Jan 8, 2013)

Filed January 8, 2013For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 8, 2013, primarily to furnish a presentation given by its CEO, Dr. Leonard S. Schleifer, at the J.P. Morgan Healthcare Conference. This filing is important for investors as it provides a direct corporate update on the company's progress and strategic direction from its leadership. While the 8-K itself does not contain new financial data or material events outside of the presentation, the furnished document is expected to cover key aspects of Regeneron's business, including its pipeline, clinical development programs, and potentially its commercial outlook. Investors should review the accompanying presentation (Exhibit 99.1) for detailed insights into Regeneron's pipeline advancements, such as updates on its key drug candidates and their respective clinical trial statuses. The presentation likely offers management's perspective on the company's achievements and future growth drivers, making it a crucial resource for understanding Regeneron's current standing and strategic priorities within the competitive biopharmaceutical landscape.

Key Highlights

  • 1Regeneron Pharmaceuticals, Inc. (REGN) filed a Form 8-K on January 8, 2013, to report an event occurring on the same date.
  • 2The primary purpose of the filing is to furnish a corporate update presentation by CEO Dr. Leonard S. Schleifer at the J.P. Morgan Healthcare Conference.
  • 3The presentation, provided as Exhibit 99.1, is the key piece of information for investors, offering insights into the company's status and strategy.
  • 4The 8-K itself is a procedural filing; the substance of the update resides within the furnished presentation.
  • 5Investors are directed to review Exhibit 99.1 for detailed information on Regeneron's business, pipeline, and strategic initiatives.
  • 6The filing is dated January 8, 2013, reflecting the date of the J.P. Morgan Healthcare Conference presentation.

Frequently Asked Questions

The main purpose of this 8-K filing is to provide investors with access to a corporate update presentation delivered by Regeneron's CEO, Dr. Leonard S. Schleifer, at the J.P. Morgan Healthcare Conference on January 8, 2013. It acts as a mechanism to disseminate management's communications to the public.

The detailed information is contained within the presentation furnished as Exhibit 99.1 to this Form 8-K filing. Investors should refer to this exhibit for insights into Regeneron's pipeline, development programs, and strategic updates.

This specific 8-K filing (filed on January 8, 2013) is primarily for furnishing a presentation. It does not typically contain new financial statements or unexpected material events beyond what is disclosed in the accompanying presentation. For detailed financial results, investors should look for the company's quarterly (10-Q) or annual (10-K) reports, or other 8-K filings specifically announcing financial outcomes.

The corporate update presentation is being delivered by Dr. Leonard S. Schleifer, M.D., Ph.D., who serves as the President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc.